Sugi Predict

Sugi Predict / Compounds / SCHEMBL4091200

SCHEMBL4091200

SCHEMBL4091200

O=C(Nc1ccc(F)cc1)N1CC2C(C1)C2Nc1ncc2cc(-c3ccccc3Cl)c(=O)n(C3CC3)c2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 4/20 0.44
▸ LCK P06239 1/20 0.44
▸ EGFR P00533 3/20 0.41
▸ ABL1 P00519 2/20 0.41
▸ PDGFRB P09619 2/20 0.41
▸ SRC P12931 2/20 0.41
▸ PDGFRA P16234 2/20 0.41
▸ FGFR1 P11362 2/20 0.41
▸ KIT P10721 1/20 0.41
▸ TNK2 Q07912 4/20 0.40
▸ CNR1 P21554 1/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ PAK1 Q13153 1/20 0.39
▸ FGFR2 P21802 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SIK1 P57059 1/20 0.38
▸ SIK2 Q9H0K1 1/20 0.38
▸ SIK3 Q9Y2K2 1/20 0.38
▸ CDK4 P11802 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095165 0.89 MAPK14 (0.55) MAPK14LCKEGFRABL1PDGFRB
SCHEMBL4089699 0.89 CNR1 (0.47) MAPK14LCKEGFRABL1PDGFRB
SCHEMBL4094757 0.86 LCK (0.50) MAPK14LCKEGFRABL1FGFR1
SCHEMBL13849306 0.86 PAK1 (0.42) MAPK14LCKEGFRABL1PDGFRB
SCHEMBL4094579 0.86 LCK (0.49) MAPK14LCKEGFRABL1FGFR1
SCHEMBL4097349 0.86 LCK (0.51) MAPK14LCKEGFRABL1FGFR1
SCHEMBL4090326 0.85 LCK (0.48) MAPK14LCKFGFR1TNK2PAK1
SCHEMBL4094209 0.84 MAPK14 (0.48) MAPK14LCKEGFRABL1PDGFRB
SCHEMBL13849289 0.83 LCK (0.46) MAPK14LCKEGFRABL1FGFR1
SCHEMBL4084196 0.82 LCK (0.48) MAPK14LCKEGFRABL1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US claimed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 — — EP claimed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 — — WO claimed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 — — EP disclosed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS TLR1, TPMT, NOD1 MAPK14 3185/4885LCK 568/4885EGFR 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.